Burns-Pipeline Review, H1 2015

Burns-Pipeline Review, H1 2015

  • Products Id :- GMDHC6269IDB
  • |
  • Pages: 96
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Burns-Pipeline Review, H1 2015


Global Markets Direct's, 'Burns-Pipeline Review, H1 2015', provides an overview of the Burns's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Burns

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Burns and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Burns pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Burns

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Burns Overview 9

Therapeutics Development 10

Pipeline Products for Burns-Overview 10

Pipeline Products for Burns-Comparative Analysis 11

Burns-Therapeutics under Development by Companies 12

Burns-Therapeutics under Investigation by Universities/Institutes 14

Burns-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Burns-Products under Development by Companies 19

Burns-Products under Investigation by Universities/Institutes 21

Burns-Companies Involved in Therapeutics Development 22

Adocia 22

AlgiPharma AS 23

Biogenomics Limited 24

Birken AG 25

CytoTools AG 26

Destiny Pharma Ltd. 27

Fibrocell Science, Inc. 28

HanAll Biopharma Co., Ltd. 29

Kasiak Research Pvt. Ltd. 30

Kuros Biosurgery AG 31

MediWound Ltd. 32

Novan, Inc. 33

Novartis AG 34

Se-cure Pharmaceuticals Ltd. 35

Stemnion, Inc 36

Stratatech Corporation 37

USV Limited 38

Vida Therapeutics Inc. 39

Xiber Science GmbH 40

Burns-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

albumin (human) (recombinant)-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Amnion Derived Cellular Cytokine Solution-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

azficel-T-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

bromelains-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BVS-857-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

coagulation factor XIVa (human)-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Drug for Dermatology and Infectious Diseases-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

epidermal growth factor biosimilar-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

G-10-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

HL-156FIB-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

IMSP-001-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

KUR-212-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Monoclonal Antibody Conjugated for Burns and Wounds-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

OleogelS-10-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Oligomer G for Wounds And Burns-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PEP-04-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Refaheal-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SC-106-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecule for Chronic Wounds and Burns-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

StrataGraft Skin Tissue-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

V-2248-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

XF-70-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Xib-1302-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Burns-Recent Pipeline Updates 80

Burns-Dormant Projects 85

Burns-Discontinued Products 87

Burns-Product Development Milestones 88

Featured News & Press Releases 88

Nov 03, 2014: MediWound Initiates Post-Marketing Study with NexoBrid to Treat Severe Burns in Pediatric Patients 88

Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health 88

May 12, 2014: MediWound Completes Recruitment of Commercial Management Team in Europe 89

May 08, 2014: MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica 91

Sep 23, 2012: Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug-NexoBrid 92

Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting 93

Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting 93

Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting 94

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

Number of Products under Development for Burns, H1 2015 10

Number of Products under Development for Burns-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Development by Companies, H1 2015 (Contd..1) 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Burns-Pipeline by Adocia, H1 2015 22

Burns-Pipeline by AlgiPharma AS, H1 2015 23

Burns-Pipeline by Biogenomics Limited, H1 2015 24

Burns-Pipeline by Birken AG, H1 2015 25

Burns-Pipeline by CytoTools AG, H1 2015 26

Burns-Pipeline by Destiny Pharma Ltd., H1 2015 27

Burns-Pipeline by Fibrocell Science, Inc., H1 2015 28

Burns-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 29

Burns-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 30

Burns-Pipeline by Kuros Biosurgery AG, H1 2015 31

Burns-Pipeline by MediWound Ltd., H1 2015 32

Burns-Pipeline by Novan, Inc., H1 2015 33

Burns-Pipeline by Novartis AG, H1 2015 34

Burns-Pipeline by Se-cure Pharmaceuticals Ltd., H1 2015 35

Burns-Pipeline by Stemnion, Inc, H1 2015 36

Burns-Pipeline by Stratatech Corporation, H1 2015 37

Burns-Pipeline by USV Limited, H1 2015 38

Burns-Pipeline by Vida Therapeutics Inc., H1 2015 39

Burns-Pipeline by Xiber Science GmbH, H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Burns Therapeutics-Recent Pipeline Updates, H1 2015 80

Burns-Dormant Projects, H1 2015 85

Burns-Dormant Projects (Contd..1), H1 2015 86

Burns-Discontinued Products, H1 2015 87

List of Figures

Number of Products under Development for Burns, H1 2015 10

Number of Products under Development for Burns-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 42

Number of Products by Stage and Top 10 Targets, H1 2015 43

Number of Products by Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 47

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com


AlgiPharma AS

Biogenomics Limited

Birken AG

CytoTools AG

Destiny Pharma Ltd.

Fibrocell Science, Inc.

HanAll Biopharma Co., Ltd.

Kasiak Research Pvt. Ltd.

Kuros Biosurgery AG

MediWound Ltd.

Novan, Inc.

Novartis AG

Se-cure Pharmaceuticals Ltd.

Stemnion, Inc

Stratatech Corporation

USV Limited

Vida Therapeutics Inc.

Xiber Science GmbH

Burns Therapeutic Products under Development, Key Players in Burns Therapeutics, Burns Pipeline Overview, Burns Pipeline, Burns Pipeline Assessment

select a license

Single User License
USD 2000 INR 136780
Site License
USD 4000 INR 273560
Corporate User License
USD 6000 INR 410340



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com